REPORT ID 3058

EMEA (Europe, Middle East and Africa) Anti-epileptic Drugs for Pediatrics Market Report 2019

Publish Date
2019
Pages
113
Format
Electronic (PDF)

In this report, the EMEA Anti-epileptic Drugs for Pediatrics market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Anti-epileptic Drugs for Pediatrics for these regions, from   2019 to 2025 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Anti-epileptic Drugs for Pediatrics market competition by top manufacturers/players, with Anti-epileptic Drugs for Pediatrics sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Mylan N.V.
    Cephalon, Inc.
    GlaxoSmithKline plc
    Janssen Pharmaceuticals
    Novartis AG
    Pfizer, Inc.
    Sanofi S.A.
    UCB Pharma Limited
    Sunovion Pharmaceuticals Limited
    Valeant Pharmaceuticals International, Inc.
    Zogenix
    GW Pharmaceuticals
    Insys
    Zynerba

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    First Generation
    Second Generation
    Third Generation

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hospital
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Anti-epileptic Drugs for Pediatrics Market  Report 2019
1 Anti-epileptic Drugs for Pediatrics Overview
    1.1 Product Overview and Scope of Anti-epileptic Drugs for Pediatrics
    1.2 Classification of Anti-epileptic Drugs for Pediatrics
        1.2.1 EMEA Anti-epileptic Drugs for Pediatrics Market Size (Sales) Comparison by Type ( 2014-2024)
        1.2.2 EMEA Anti-epileptic Drugs for Pediatrics Market Size (Sales) Market Share by Type (Product Category)  in 2018
        1.2.3 First Generation
        1.2.4 Second Generation
        1.2.5 Third Generation
    1.3 EMEA Anti-epileptic Drugs for Pediatrics Market by Application/End Users
        1.3.1 EMEA Anti-epileptic Drugs for Pediatrics Sales (Volume) and Market Share Comparison by Application ( 2014-2024
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 EMEA Anti-epileptic Drugs for Pediatrics Market by Region
        1.4.1 EMEA Anti-epileptic Drugs for Pediatrics Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 Europe Status and Prospect ( 2014-2024)
        1.4.3 Middle East Status and Prospect ( 2014-2024)
        1.4.4 Africa Status and Prospect ( 2014-2024)
    1.5 EMEA Market Size (Value and Volume) of Anti-epileptic Drugs for Pediatrics ( 2014-2024)
        1.5.1 EMEA Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2024)
        1.5.2 EMEA Anti-epileptic Drugs for Pediatrics Revenue and Growth Rate ( 2014-2024)

2 EMEA Anti-epileptic Drugs for Pediatrics Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Anti-epileptic Drugs for Pediatrics Market Competition by Players/Manufacturers
        2.1.1 EMEA Anti-epileptic Drugs for Pediatrics Sales Volume and Market Share of Major Players ( 2014-2019)
        2.1.2 EMEA Anti-epileptic Drugs for Pediatrics Revenue and Share by Players ( 2014-2019)
        2.1.3 EMEA Anti-epileptic Drugs for Pediatrics Sale Price by Players ( 2014-2019)
    2.2 EMEA Anti-epileptic Drugs for Pediatrics (Volume and Value) by Type/Product Category
        2.2.1 EMEA Anti-epileptic Drugs for Pediatrics Sales and Market Share by Type ( 2014-2019)
        2.2.2 EMEA Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Type ( 2014-2019)
        2.2.3 EMEA Anti-epileptic Drugs for Pediatrics Sale Price by Type ( 2014-2019)
    2.3 EMEA Anti-epileptic Drugs for Pediatrics (Volume) by Application
    2.4 EMEA Anti-epileptic Drugs for Pediatrics (Volume and Value) by Region
        2.4.1 EMEA Anti-epileptic Drugs for Pediatrics Sales and Market Share by Region ( 2014-2019)
        2.4.2 EMEA Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Region ( 2014-2019)
        2.4.3 EMEA Anti-epileptic Drugs for Pediatrics Sales Price by Region ( 2014-2019)

3 Europe Anti-epileptic Drugs for Pediatrics (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Anti-epileptic Drugs for Pediatrics Sales and Value ( 2014-2019)
        3.1.1 Europe Anti-epileptic Drugs for Pediatrics Sales Volume and Growth Rate ( 2014-2019)
        3.1.2 Europe Anti-epileptic Drugs for Pediatrics Revenue and Growth Rate ( 2014-2019)
    3.2 Europe Anti-epileptic Drugs for Pediatrics Sales and Market Share by Type
    3.3 Europe Anti-epileptic Drugs for Pediatrics Sales and Market Share by Application
    3.4 Europe Anti-epileptic Drugs for Pediatrics Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Anti-epileptic Drugs for Pediatrics Sales Volume by Countries ( 2014-2019)
        3.4.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Countries ( 2014-2019)
        3.4.3 Germany Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        3.4.4 France Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        3.4.5 UK Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        3.4.6 Russia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        3.4.7 Italy Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        3.4.8 Benelux Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)

4 Middle East Anti-epileptic Drugs for Pediatrics (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Anti-epileptic Drugs for Pediatrics Sales and Value ( 2014-2019)
        4.1.1 Middle East Anti-epileptic Drugs for Pediatrics Sales Volume and Growth Rate ( 2014-2019)
        4.1.2 Middle East Anti-epileptic Drugs for Pediatrics Revenue and Growth Rate ( 2014-2019)
    4.2 Middle East Anti-epileptic Drugs for Pediatrics Sales and Market Share by Type
    4.3 Middle East Anti-epileptic Drugs for Pediatrics Sales and Market Share by Application
    4.4 Middle East Anti-epileptic Drugs for Pediatrics Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Anti-epileptic Drugs for Pediatrics Sales Volume by Countries ( 2014-2019)
        4.4.2 Middle East Anti-epileptic Drugs for Pediatrics Revenue by Countries ( 2014-2019)
        4.4.3 Saudi Arabia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        4.4.4 Israel Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        4.4.5 UAE Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        4.4.6 Iran Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)

5 Africa Anti-epileptic Drugs for Pediatrics (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Anti-epileptic Drugs for Pediatrics Sales and Value ( 2014-2019)
        5.1.1 Africa Anti-epileptic Drugs for Pediatrics Sales Volume and Growth Rate ( 2014-2019)
        5.1.2 Africa Anti-epileptic Drugs for Pediatrics Revenue and Growth Rate ( 2014-2019)
    5.2 Africa Anti-epileptic Drugs for Pediatrics Sales and Market Share by Type
    5.3 Africa Anti-epileptic Drugs for Pediatrics Sales and Market Share by Application
    5.4 Africa Anti-epileptic Drugs for Pediatrics Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Anti-epileptic Drugs for Pediatrics Sales Volume by Countries ( 2014-2019)
        5.4.2 Africa Anti-epileptic Drugs for Pediatrics Revenue by Countries ( 2014-2019)
        5.4.3 South Africa Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        5.4.4 Nigeria Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        5.4.5 Egypt Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)
        5.4.6 Algeria Anti-epileptic Drugs for Pediatrics Sales and Growth Rate ( 2014-2019)

6 EMEA Anti-epileptic Drugs for Pediatrics Manufacturers/Players Profiles and Sales Data
    6.1 Mylan N.V.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Mylan N.V. Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Cephalon, Inc.
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Cephalon, Inc. Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 GlaxoSmithKline plc
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Janssen Pharmaceuticals
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Novartis AG
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 Pfizer, Inc.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Pfizer, Inc. Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Sanofi S.A.
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Sanofi S.A. Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 UCB Pharma Limited
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 Sunovion Pharmaceuticals Limited
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 Valeant Pharmaceuticals International, Inc.
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Anti-epileptic Drugs for Pediatrics Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Valeant Pharmaceuticals International, Inc. Anti-epileptic Drugs for Pediatrics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview
    6.11 Zogenix
    6.12 GW Pharmaceuticals
    6.13 Insys
    6.14 Zynerba

7 Anti-epileptic Drugs for Pediatrics Manufacturing Cost Analysis
    7.1 Anti-epileptic Drugs for Pediatrics Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Anti-epileptic Drugs for Pediatrics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Anti-epileptic Drugs for Pediatrics Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Anti-epileptic Drugs for Pediatrics Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Anti-epileptic Drugs for Pediatrics Market Forecast ( 2019-2025)
    11.1 EMEA Anti-epileptic Drugs for Pediatrics Sales, Revenue and Price Forecast ( 2019-2025)
        11.1.1 EMEA Anti-epileptic Drugs for Pediatrics Sales and Growth Rate Forecast ( 2019-2025)
        11.1.2 EMEA Anti-epileptic Drugs for Pediatrics Revenue and Growth Rate Forecast ( 2019-2025)
        11.1.3 EMEA Anti-epileptic Drugs for Pediatrics Price and Trend Forecast ( 2019-2025)
    11.2 EMEA Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.3 Europe Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.4 Middle Eastt Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.5 Africa Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.6 EMEA Anti-epileptic Drugs for Pediatrics Sales Forecast by Type ( 2019-2025)
    11.7 EMEA Anti-epileptic Drugs for Pediatrics Sales Forecast by Application ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer